Literature DB >> 17698709

Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.

Karine Nguyen1, Guillaume Bassez, Martin Krahn, Rafaelle Bernard, Pascal Laforêt, Véronique Labelle, Jon Andoni Urtizberea, Dominique Figarella-Branger, Norma Romero, Shahram Attarian, France Leturcq, Jean Pouget, Nicolas Lévy, Bruno Eymard.   

Abstract

OBJECTIVE: To describe the phenotypic spectrum of dysferlin (DYSF) gene mutations (which cause dysferlinopathies, autosomal recessive muscular dystrophies) in patients with a dysferlin protein deficiency.
DESIGN: Clinical, biological, and pathological data from 40 patients were reviewed. The diagnosis of dysferlinopathy was based on the absence or strong reduction of dysferlin in muscle, and confirmed by mutational screening of the DYSF gene.
SETTING: Two French neuromuscular diseases centers (in Paris and Marseilles).
RESULTS: Two main dysferlinopathy phenotypes are well recognized: Miyoshi myopathy and limb-girdle muscular dystrophy type 2B. Typical Miyoshi myopathy and limb-girdle muscular dystrophy type 2B were found in 20 (50%) patients only. Unusual phenotypes included a mixed phenotype, referred to as "proximodistal," combining distal and proximal onset in 14 (35%) patients, pseudometabolic myopathy in 4 (10%), and asymptomatic hyperCKemia (an increased serum creatine kinase level) in 2 (5%). The disease may worsen rapidly, and 10 (25%) patients were initially misdiagnosed as having polymyositis. We suggest a relationship between proximodistal phenotype, inflammation, and severity.
CONCLUSION: In addition to typical Miyoshi myopathy and limb-girdle muscular dystrophy type 2B, dysferlinopathies are a clinically heterogeneous group of disorders ranging from asymptomatism to severe functional disability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698709     DOI: 10.1001/archneur.64.8.1176

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  68 in total

1.  Myopathy caused by anoctamin 5 mutations and necrotizing vasculitis.

Authors:  Isabelle Pénisson-Besnier; Jean-Paul Saint-André; Debbie Hicks; Anna Sarkozy; Anne Croué; Judith Hudson; Hanns Lochmüller; Frédéric Dubas
Journal:  J Neurol       Date:  2012-04-19       Impact factor: 4.849

2.  Autoantibody profiles in two patients with non-autoimmune muscle disease implicate a role for gliadin autoreactivity.

Authors:  Nancy J Olsen; Heidi Prather; Quan-Zhen Li; Dennis K Burns
Journal:  Neuromuscul Disord       Date:  2010-01-27       Impact factor: 4.296

Review 3.  Ferlins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair.

Authors:  Angela Lek; Frances J Evesson; R Bryan Sutton; Kathryn N North; Sandra T Cooper
Journal:  Traffic       Date:  2011-09-06       Impact factor: 6.215

Review 4.  Membrane Repair: Mechanisms and Pathophysiology.

Authors:  Sandra T Cooper; Paul L McNeil
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

5.  Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.

Authors:  Bilal A Azakir; Sabrina Di Fulvio; Jochen Kinter; Michael Sinnreich
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

6.  ["Therapy-resistant polymyositis" - is the diagnosis correct?]

Authors:  G Ceccon; H C Lehmann; E Neuen-Jacob; G Meng; G R Fink; G Wunderlich
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

7.  Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation.

Authors:  Joseph J Belanto; Silvia V Diaz-Perez; Clara E Magyar; Michele M Maxwell; Yasemin Yilmaz; Kasey Topp; Guney Boso; Catriona H Jamieson; Nicholas A Cacalano; Christina A M Jamieson
Journal:  Neuromuscul Disord       Date:  2010-01-18       Impact factor: 4.296

8.  Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.

Authors:  Kanneboyina Nagaraju; Rashmi Rawat; Edina Veszelovszky; Rachana Thapliyal; Akanchha Kesari; Susan Sparks; Nina Raben; Paul Plotz; Eric P Hoffman
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

9.  Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy.

Authors:  Yen-Hui Chiu; Mark A Hornsey; Lars Klinge; Louise H Jørgensen; Steven H Laval; Richard Charlton; Rita Barresi; Volker Straub; Hanns Lochmüller; Kate Bushby
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

10.  New aspects on patients affected by dysferlin deficient muscular dystrophy.

Authors:  Lars Klinge; Ahmed Aboumousa; Michelle Eagle; Judith Hudson; Anna Sarkozy; Gianluca Vita; Richard Charlton; Mark Roberts; Volker Straub; Rita Barresi; Hanns Lochmüller; Kate Bushby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-14       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.